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Alzheimer’s disease (AD) and other neurodegenerative disorders
are associated with the cytoplasmic aggregation of microtubule-
associated protein tau. Recent evidence supports transcellular
transfer of tau misfolding (seeding) as the mechanism of spread
within an affected brain, a process reminiscent of viral infection.
However, whereas microbial pathogens can be recognized as non-
self by immune receptors, misfolded protein assemblies evade detec-
tion, as they are host-derived. Here, we show that when misfolded
tau assemblies enter the cell, they can be detected and neutralized via
a danger response mediated by tau-associated antibodies and the
cytosolic Fc receptor tripartite motif protein 21 (TRIM21). We devel-
oped fluorescent, morphology-based seeding assays that allow the
formation of pathological tau aggregates to be measured in situ
within 24 h in the presence of picomolar concentrations of tau seeds.
We found that anti-tau antibodies accompany tau seeds into the cell,
where they recruit TRIM21 shortly after entry. After binding, TRIM21
neutralizes tau seeds through the activity of the proteasome and the
AAA ATPase p97/VCP in a similar manner to infectious viruses. These
results establish that intracellular antiviral immunity can be redirected
against host-origin endopathogens involved in neurodegeneration.
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The cell’s ability to identify intracellular viruses and bacteriarelies on the detection of pathogen-associated molecular
patterns (PAMPs) by specialized host receptors. Although highly
effective at detecting microbial pathogens, this strategy is poorly
equipped to identify host-derived pathogenic species such as
aggregated proteins. As an alternative to PAMP detection, re-
cent work has demonstrated that mammalian cells can use host-
derived serum proteins, which are normally excluded from the
cell interior, to target invading viruses and bacteria in the cytosol.
For instance, nonenveloped viruses and bacteria carry antibodies
with them into the cytoplasm during infection. These translocated
antibodies are then sensed by the cytoplasmically expressed anti-
body receptor TRIM21 (tripartite motif protein 21), which binds
with subnanomolar affinity to the antibody Fc domain (1–4). After
binding to antibody, TRIM21 triggers a potent neutralization re-
sponse that inhibits viral infection. Neutralization of infection is
accompanied by degradation of viral components, which requires
the activity of the proteasome and the molecular unfoldase, valosin-
containing protein (VCP) or p97 (1, 5). Detection of viruses and
bacteria by TRIM21 does not rely on microbial PAMPs, as model
substrates such as antibody-coated latex beads can be bound and
detected by TRIM21 (1, 3). We therefore hypothesized that the
intracellular innate immune system could be repurposed to rec-
ognize and degrade host-derived pathogenic proteins.
Microtubule-associated protein tau occurs in an assembled
and hyperphosphorylated state in the cytoplasm of neurons and
glial cells in Alzheimer’s disease (AD), progressive supranuclear
palsy, chronic traumatic encephalopathy, and other neurode-
generative disorders (6). Tau assemblies applied to the extra-
cellular spaces can seed further aggregation: injection of tau
assemblies into the brains of tau transgenic mice promotes the
aggregation of intracellular tau (7), and ectopic addition of
recombinant tau assemblies promotes the aggregation of in-
tracellular pools in cultured cells (8, 9). Consistent with trans-
cellular propagation of misfolding, tau pathology in AD spreads
between connected regions of the brain in a stereotyped manner
(10). Seeded propagation of misfolded tau is therefore proposed
to underlie many common neurodegenerative disorders. Akin to
viral infection, this model of seeded tau propagation relies on the
physical transfer of tau assemblies between cells, and is therefore
potentially susceptible to interception by antibody. The broad
tissue expression of TRIM21 and its ultrahigh affinity for Fc imply
that intracellular antibodies will be bound by TRIM21 whenever
they occur. Numerous intracellular entities may therefore be tar-
geted by TRIM21, including DNA and RNA viruses (1, 11, 12),
cytosolic bacteria (3), and soluble host proteins, including an Fc
fragment (5) and a cis-tau conformer (13). However, it is not
known whether self-propagating protein assemblies are suscepti-
ble to neutralization by TRIM21.
Here we report the development of highly sensitive tau seeding
assays, which measure the ability of extracellular tau assemblies to
promote the conversion of intracellular, full-length tau from a sol-
uble to aggregated state after their entry to the cell. We demon-
strate that tau seeds that enter the cell with attached antibody are
rapidly bound and inactivated by TRIM21. Our results demon-
strate that given an appropriate danger signal, here antibody, the
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intracellular immune system is capable of detecting and inactivating
self-propagating protein assemblies.
Results
TRIM21 Is Expressed in Neural Cells. Transcriptomic and immuno-
histochemical analyses suggest that the cytosolic Fc receptor
TRIM21 is expressed at low levels in brain tissue (14, 15). To test
whether this basal expression is sufficient for protective in-
tracellular immunity, we challenged primary mouse neural cul-
tures with adenovirus or adenovirus treated with monoclonal
antibody 9C12, a model system for intracellular neutralization (2).
In neurons derived from wild-type (WT) mice, 9C12 conferred a 40-
fold block to infection (Fig. 1A). However, in neurons derived from
Trim21−/− mice, a 12-fold block to infection was observed. Basal
Trim21 levels can therefore provide a significant block to infection
in neurons. This finding is in agreement with previous findings that
Trim21 is expressed and active in primary neurons (13). Trim21 is
an IFN-stimulated gene whose expression levels determine the
potency of intracellular neutralization (2). We tested the effect of
type I, II, or III interferons on intracellular neutralization in primary
neurons. IFN-α (type I) and IFN-β (type II), but not IFN-λ (type
III), up-regulated Trim21 expression (Fig. 1B). IFN-stimulated up-
regulation of Trim21 substantially potentiated neutralization,
resulting in a >700-fold reduction of infection by antibody in
stimulated WT cells (Fig. 1C). In contrast, all IFNs exerted little
effect on neutralization in Trim21−/− cells. Levels of neutraliza-
tion were correlated with, and almost entirely accounted for, by
levels of Trim21 mRNA (R2 = 0.94) (Fig. 1D). Importantly,
TRIM21 mediated comparable levels of adenovirus neutraliza-
tion in human H4 neuroglioma and SHSY-5Y neuroblastoma
cells, in addition to HeLa and HEK293 lines (Fig. 1E), demon-
strating that TRIM21 is widely expressed and active in diverse
tissues, including CNS and neural derived cells.
Sensitive in Vitro Tau Seeding Assay. The study of seeded tau
propagation relies on transgenic mouse models, in which disease
progression is slow and the contribution of seeded vs. sponta-
neous aggregation is often unclear. Alternatively, in vitro assays
allow these contributions to be quantified and dissected, but
existing methods rely on aggregation-prone fragments of tau,
have suffered from low signal-to-noise ratios, or require labori-
ous biochemical fractionation, which is not amenable to detailed
study. We therefore developed a high-content microscopy-based
assay using HEK293 cells stably expressing the 0N4R isoform of
human tau, bearing frontotemporal dementia-associated muta-
tion P301S with a C-terminal venus tag. Addition of recombinant
heparin-assembled P301S tau promoted the conversion of tau-
venus from a disperse distribution to bright foci (Fig. 2A). To
demonstrate that these foci are associated with tau aggregation,
the sarkosyl-insoluble fraction was prepared from cell homoge-
nates. Addition of tau assemblies resulted in a proportion of tau
pelleting in the sarkosyl-insoluble fraction, and the venus tag did
not substantially alter this process (Fig. 2B and Fig. S1). To in-
vestigate whether tau-venus foci recapitulated the pathological
characteristics of tauopathies, we used immunostaining for
phosphorylated and fibril-specific epitopes. A pan-tau antibody,
HT7, colocalized with tau-venus in both untreated cells and
seeded cells (Fig. S2). In contrast, tau-venus foci that occurred
after seeding, but not soluble tau-venus, were stained by anti-
bodies that depend on phosphorylation of their antigens, anti-
pS422 (Fig. S2) (16) and AT100 (pT212, pS214, pT217), which is
specific for pathological tau structures (Fig. 2C) (17). To confirm
that intracellular expressed tau-venus, rather than seed, was the
target of hyperphosphorylation, we challenged cells with tau
assemblies bearing point mutation S422A. Phosphorylation at
S422 was detected within 12 h of challenge (Fig. 2D), confirming
aggregation and hyperphosphorylation of intracellular expressed
tau. These observations demonstrate a seeding assay that reca-
pitulates both the aggregation and hyperphosphorylation ob-
served in diseased brains in a widely used human cell line.
Furthermore, the results support the close temporal association
of intracellular aggregation and hyperphosphorylation.
Cytoplasmic Delivery of Tau Is Rate-Limiting to Seeding. Previous
observations in cell-based models of tau seeding support the
hypothesis that entry to the cell, rather than aggregation itself, is
rate-limiting (9). We used cationic lipids (Lipofectamine 2000;
LF) to promote uptake and disrupt endosomal membranes. LF
substantially increased both the rate and overall level of aggre-
gation in our assay (Fig. 2E), using automated image analysis
(Fig. S2). The data suggest that seeded aggregation is a rapid
process that occurs largely within 12 h, whereas uptake and
endosomal rupture are inefficient and, in the absence of LF,
rate-limiting. LF increased the percentage of seeded cells in a
manner proportional to its ability to deliver a luciferase-encoding
plasmid (Fig. 2F and Fig. S3), consistent with intracellular de-
livery of tau assemblies being the cause of increased seeding by
LF. In the presence of LF, seeding increased in a dose-dependent
manner with tau concentration over more than three orders of
magnitude (Fig. 2G). Statistically significant seeding, relative to a
Fig. 1. Cells derived from neural tissues exert inducible intracellular neu-
tralization via TRIM21. (A) Mouse primary neural cultures derived from WT
or Trim21−/− C57BL/6 E18 embryos were challenged with a titration of ad-
enovirus-RFP that was pretreated with PBS or anti-hexon antibody 9C12.
(B) Relative levels of Trim21 mRNA in WT neural cultures after stimulation
with the indicated IFN compared with untreated (UT) cells, normalized to
levels of β-actin mRNA. (C) Levels of neutralization in WT or Trim21−/− neural
cultures treated as in B. Fold neutralization was calculated by dividing the
level of infection with PBS-treated virus by that of 9C12-treated virus.
(D) Fold neutralization observed after IFN stimulation is correlated with
Trim21 mRNA levels (Pearson r = 0.99; P < 0.001; R2 = 0.94). (E) Fold neu-
tralization of adenovirus by 9C12 in H4, amodel of humanmicroglia; SHSY-5Y, a
human cell line with properties of neurons and HeLa and HEK293, commonly
used human cell lines. TRIM21 was deleted by CRISPR/Cas9 (T21 KO).





















LF-treated control, was detected using 23-pM tau assemblies. In
contrast, the addition of monomeric tau did not induce seeding
(Fig. 2H). The sarkosyl-insoluble fraction of Alzheimer’s dis-
eased brain tissue was also competent at inducing seeding (Fig.
2I). These data demonstrate a sensitive and quantitative assay
using full-length tau that responds to the presence of tau as-
semblies, both recombinant and clinically derived, by propagat-
ing intracellular, phosphorylated tau aggregates. Moreover, they
demonstrate that cytosolic entry is rate-limiting and that once
inside the cell, trace amounts of seed, left unrestricted, are ca-
pable of rapidly initiating tau aggregation.
Antibodies Prevent Seeding but Poorly Block Entry. Next, we used
our assay to identify antibodies that reduce seeding. A panel of
phosphorylation-independent anti-tau and control antibodies
(Table S1) was screened, of which mouse monoclonal IgG1, 5A6
(18), and rabbit polyclonal antibody, BR134 (19), were found to
prevent seeding by recombinant P301S tau assemblies in the
absence of LF (Fig. 3 A and B). The ability of 5A6 and BR134 to
prevent binding and uptake of AlexaFluor488-labeled tau as-
semblies to cells was tested. Binding (at 4 °C) and uptake (at
37 °C) were marginally reduced (∼20%) by 5A6, but not by
BR134 (Fig. 3C). Consistent with previous observations (20),
these results suggest that entry-blocking contributes to neutrali-
zation. However, for both 5A6 and BR134, the majority of neu-
tralization was not accounted for by this mechanism. Moreover,
neutralization was observed when assembled P301S tau-antibody
complexes were introduced by LF (Fig. 3D). Together, these results
suggest that neutralization by 5A6 and BR134 occurs largely postentry.
TRIM21 Neutralizes Tau Seeding. Cytosolic Fc receptor TRIM21
mediates the highly efficient postentry neutralization of anti-
body-bound nonenveloped viruses and soluble toxic tau precursors
(1, 2, 13, 21). To investigate whether tau seeding can be neutralized
by TRIM21, we used CRISPR/Cas9 to disrupt TRIM21 in HEK293
cells expressing P301S tau-venus and confirmed protein knockout
by immunoblot (Fig. 4A). HEK293 cells take up tau aggregates by
macropinocytosis (22), but lack expression of FcγRs, permitting
analysis of neutralization in the absence of cell surface antibody
receptors. Disruption of TRIM21 by CRISPR/Cas9 reduced the
ability of mouse monoclonal antibody 9C12 to neutralize adenovirus
infection (Fig. 1E), as has previously been demonstrated by small
hairpin RNA and genetic ablation (2). Neutralization of tau seeding
Fig. 2. Exogenously added tau assemblies induce aggregation and phos-
phorylation of intracellular tau. (A) P301S tau-venus expressed in HEK293
cells with or without addition of heparin-assembled recombinant P301S tau
to culture supernatant. (B) Sarkosyl insoluble tau 3 d after challenge with
P301S tau assemblies or mock treatment. Levels determined by Western blot
and normalized to total tau. (C) Cells treated as in A stained with phos-
phorylated tau fibril-specific antibody AT100. (D) Levels of staining with anti-
pS422 12 h postchallenge with P301S/S422A tau assemblies. (E) Time course
of seeding by 100 nM P301S tau assemblies in the presence or absence of
0.5 μL LF. (F) Percentage HEK293 cells that exhibit aggregated tau-venus 3 d
postchallenge with 200 nM P301S tau assemblies with indicated dose of LF.
(G–I) Percentage of cells seeded after challenge in the presence of LF with
(G) a titration of P301S tau assemblies, (H) 50 nM monomeric or aggregated
P301S tau, or (I) AD brain sarkosyl insoluble (SI) fraction. *Unpaired t test P <
0.05; ***P < 0.0001. Error denotes SEM. In B, D, and F, n = 3 replicate ex-
periments; in E and G–I, n = 9–24 fields per condition. (Scale bars, 20 μm.)
Fig. 3. Neutralization of tau seeding can occur independent of entry
blocking. (A) Percentage HEK293 tau-venus cells seeded 5 d after challenge
with P301S tau assemblies that were mixed with indicated antibodies for 1 h
before addition to culture supernatant. (B) Tau epitopes identified by 5A6
and BR134. (C) Relative fluorescence of HEK293 cells treated with Alexa488-
labeled tau assemblies at indicated temperature. (D) Percentage HEK293
tau-venus cells seeded after challenge with 100 nM P301S tau assemblies
incubated with indicated antibody in the presence of LF. **Unpaired t test
P < 0.01; ***P < 0.0001. Error denotes SEM. In A and G, n = 10–20 fields per
condition; C–F, duplicate experiments. (Scale bars, 20 μm.)
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by 5A6 and BR134 was significantly reduced in cells that lacked
TRIM21 (Fig. 4B). TRIM21-mediated neutralization of adenovirus
proceeds without a lag phase and is dose-dependent until reaching a
plateau termed the “persistent fraction.” This represents a pro-
portion of infection that cannot be prevented, but whose level is
dependent on TRIM21 expression levels (2, 23). TRIM21-mediated
neutralization of tau seeding occurred with log-linear dynamics and
without a detectable lag-phase (Fig. 4C). This suggests that, as in
the case of adenovirus neutralization, a threshold antibody stoichi-
ometry is not required, but that neutralization increases incremen-
tally with antibody occupancy. A persistent fraction was observed
for tau neutralization, whose level was increased in cells lacking
TRIM21 (Fig. 4D). Thus, neutralization of tau seeding occurs with
similar dynamics as neutralization of adenovirus infection. To de-
termine whether the nature of the tau seed affects neutralization,
we tested whether TRIM21 can neutralize the sarkosyl-insoluble
fraction from AD brain, which contains tau fibrils. We found that
BR134 reduced seeding in unmodified HEK293 cells, but provided
no protection when TRIM21 was deleted (Fig. 4E). Thus, tau as-
semblies from recombinant and clinical samples can be neutralized
in the intracellular domain in a similar manner to viral infection.
TRIM21 Is Rapidly Recruited to Antibody-Bound Tau Assemblies. The
fast kinetics of seeded tau aggregation imply that for TRIM21 to
be effective, it must be rapidly recruited to incoming antibody-
coated seeds. To test this, we challenged HEK293 cells expressing
myc-tagged TRIM21 with tau assemblies and examined the lo-
calization of TRIM21 after 4 h (Fig. S4 and Fig. 4F). Alterna-
tively, we challenged HEK293 cells expressing mCherry-TRIM21
with the sarkosyl-insoluble fraction prepared from seeded tau-
venus-expressing cells and fixed cells at 1 h (Fig. 4G). In both
cases, TRIM21 adopted a disperse cytoplasmic distribution in
cells that were treated with unlabeled tau assemblies. However,
TRIM21 reorganized to bright foci surrounding antibody-coated
tau assemblies during challenge. As has been observed for anti-
body-bound viruses and bacteria (1, 3), a subset of antibody-bound
P301S tau assemblies did not colocalize with TRIM21 and is likely
endosomal. We conclude that TRIM21 is recruited to tau assem-
blies shortly after their entry to the cytoplasm.
TRIM21 Is the Sole Protective Fc Receptor in a Human Neuronal Cell
Line. It has previously been demonstrated that antibody receptors
FcγRII/III expressed on the surface of neurons in brain slices
mediates uptake of uncomplexed anti-tau antibodies (24, 25). The
internalized antibodies are proposed to interact with cellular tau
pools in a compartment that stains positive for markers of the
endolysosome. Such a mechanism could potentially affect the
seeded aggregation of cytosolic tau, either by increasing the uptake
of tau–antibody immune complexes to neurons or by diverting im-
mune complexes to endolysosomal degradation pathways. We
therefore addressed whether cell surface Fc receptors enhance or
interfere with seeding/neutralization in a human neuronal cell line.
We established a seeding assay in the human neuroblastoma cell
line SHSY-5Y by expressing P301S tau-venus in a similar manner as
in HEK293s (Fig. S5). Seeding was observed in both the presence
and absence of lipofectamine and cells bearing seeded tau aggre-
gates stained positive with AT100. The presence of excess IgG or an
antibody that blocks FcγRII/III did not alter observed levels of
seeding by tau–antibody complexes (Fig. 5A). These data are
suggestive of an absence of FcγR activity in these cells. Directly
testing for the expression FcγRs in SHSY-5Y cells revealed
minimal or no expression for both high-affinity (CD64, FcγRIB)
and low-affinity (CD32 FcγRIIA; CD16a, FcγRIIIA; CD16b,
FcγRIIIB) Fc receptors, similar to HEK293s (Fig. 5B). In con-
trast, we observed strong FcγRI and FcγRII expression in the
monocyte-derived cell line THP-1, consistent with its role as an
antigen-presenting cell. Conversely, TRIM21 mRNA was de-
tected in all cell lines at comparable levels. These findings are in
agreement with data from cultured mouse neurons and tran-
scriptomic databases, where cell surface FcγR expression in neurons
is found to be very low or absent (14, 26). Tau neutralization in
SHSY-5Y cells occurred similarly to HEK293s. In both the pres-
ence and absence of LF, seeding was neutralized by 5A6, but sig-
nificantly reduced on TRIM21 depletion (Fig. 5 C–E). Thus,
TRIM21 appears to be the only FcR expressed and functional in
neurons, and therefore the sole receptor capable of effecting the
neutralization of prion-like proteins that replicate in the cytoplasm
of neurons.
Neutralization of Tau Seeding Is Proteasome- and VCP-Dependent. To
investigate whether neutralization of tau seeding follows a sim-
ilar cofactor dependency as virus neutralization, we treated cells
with the proteasomal inhibitor MG132. Under these conditions,
neutralization of tau seeding was significantly reduced, although
not completely inhibited (Fig. 6A). To examine the contribution of
Fig. 4. Tau seeding is neutralized via TRIM21. (A) Im-
munoblot for TRIM21 in HEK293 tau-venus cells treated
with control vector expressing Cas9 only or with addi-
tional TRIM21-directed guide RNA. (B) Relative levels of
seeding by recombinant P301S tau assemblies after
treatment with indicated antibody in the presence of
LF. (C) Titration of 5A6 against tau seeding in HEK293.
(D) Titration of 5A6 or isotype control antibody 9C12
against tau seeding. (E) Relative level of seeding by AD
brain sarkosyl insoluble fraction alone or in complex
with BR134 in HEK293 cells in the presence of LF.
(F) Percentage of tau aggregates within cell boundaries
that colocalize with myc-TRIM21. (G) Confocal micro-
scope images of cells expressing mCherry-TRIM21 fixed
1 h after application of tau-venus assemblies purified
from human cells in the presence of LF. (Scale bar,
5 μm.) **Unpaired t test P < 0.01; ***P < 0.0001. Error
denotes SEM. In B–E, n = 8–12 fields per condition; in G,
n = 13 fields per condition. n.d., none detected.





















the molecular unfoldase VCP, we used the inhibitor N2,N4-diben-
zylquinazoline-2,4-diamine (DBeQ) (27) or its derivative ML240
(28). Treatment with these compounds almost completely reversed
neutralization (Fig. 6 B and C). Depletion of VCP by siRNA also
reduced levels of neutralization, confirming VCP dependence
(Fig. 6 D and E). These results demonstrate that neutralization of
tau seeding occurs with similar cofactor dependencies as viral
neutralization. However, the results suggest a more prominent
role for VCP compared with the proteasome, as inhibition of
neutralization was greater with inhibitors of the former. VCP has a
role in both proteasomal and macroautophagy degradation
pathways. We therefore tested whether TRIM21 also exerts
neutralization via autophagy. We used siRNA depletion of the
ubiquitin-like protein ATG12, whose conjugation to ATG5 is an
upstream requirement for the formation of autophagosomes, to
test the effect of impaired autophagy on intracellular neutrali-
zation. However, despite preventing the formation of GFP-LC3
puncta after starvation (Fig. S6), ATG12 depletion did not im-
pair the neutralization of tau seeding by 5A6 (Fig. 6F). The role
of VCP in neutralization of tau seeding is therefore likely to be
independent of autophagy. Further supporting this finding,
chemical inhibition of autophagy or lysosomal acidification did
not prevent neutralization of tau seeding (Fig. 6G and Fig. S6).
Overall, these results demonstrate that, similar to viruses, anti-
body-labeled tau aggregates are neutralized in a proteasome-
and VCP-dependent manner in the intracellular environment.
Discussion
We have developed high-content quantitative assays for mea-
suring cytosolic tau aggregation in situ. Whereas the introduction
of tau assemblies to the cytoplasm induced rapid aggregation,
the presence of anti-tau antibodies diverted tau seeds to a
neutralization pathway that substantially reduced their seeding
capacity (diagram in Fig. S7). This inhibition relied on the detection
of antibody-bound tau by the cytosolic Fc receptor TRIM21, which
exerted neutralization activity in concert with known intracellular
neutralization machinery, the molecular unfoldase VCP and the
proteasome. Intracellular neutralization occurred rapidly, before
tau hyperphosphorylation, and was observed for tau assemblies
prepared from recombinant or AD brain-derived sources. These
results demonstrate that, despite lacking PAMPs, pathogenic pro-
tein assemblies can be recognized and destroyed by the cell if
presented in context with a danger signal, intracellular antibody.
Thus, intracellular antiviral immunity can be repurposed to protect
against self-propagating protein misfolding.
Large tau aggregates are refractory to proteasomal activity, and
their turnover is thought to rely primarily on macroautophagy (29,
30). In contrast, seeds are reported to be short fibrils containing >10
copies of tau (31). Our results suggest that tau seeds are substrates
for proteasomal degradation if targeted rapidly after cell entry.
Thus, targeting seeds rather than established aggregates may be a
more effective strategy for preventing spreading tau aggregation.
Importantly, we observed that the inhibition of tau aggregation was
more dependent on VCP than the proteasome. This is in contrast to
adenovirus neutralization, in which proteasome and VCP activities
are equally critical (1, 5). VCP has been linked to both proteasomal
degradation and autophagy; however, we did not observe any re-
duction in the neutralization of aggregation under conditions where
autophagy was prevented. Instead, it is possible that VCP exerts its
effect by unfolding tau seeds to prevent them from catalyzing ag-
gregation. This would be consistent with the enzyme’s known
unfoldase activity (32), and with altered tau conformations being
the drivers of seeded aggregation.
The discovery that antibodies are capable of preventing cyto-
plasmic tau aggregation is significant to the development of im-
munotherapy for AD and other tau pathologies. In transgenic
mouse models, passive transfer of tau-specific antibodies can reduce
tau pathology (20, 33–35). Similar approaches in humans are being
widely studied as potential treatments for neurodegeneration (36).
Fig. 5. TRIM21 is the only protective Fc receptor in SHSY-5Y neuroblastoma cells.
(A) Levels of seeding in SHSY-5Y cells treated as indicated in the absence of LF.
Excess mouse IgG (mIgG) or an antibody that blocks the low-affinity FcγRII and
FcγRIII did not alter levels of seeding after challenge with tau-5A6 complexes.
(B) Levels of indicated mRNA transcripts in HEK293, SHSY-5Y, and the monocyte
cell line THP-1. Relative levels were determined by RT-qPCR, using the −ΔCt
method relative to β-actin (ACTB). (C) Immunoblot for TRIM21 in SHSY-5Y cells
that were treated with Cas9 only or with an additional TRIM21-directed guide
RNA. (D and E) Relative levels of seeding in SHSY-5Y cells after challenge with tau
assemblies that were pretreated with PBS, nonspecific mouse IgG, or tau-specific
antibody 5A6 in the (D) absence and (E) presence of LF. **Unpaired t test P < 0.01;
***P < 0.0001. Error denotes SEM. In A and E, n = 12 fields per condition; in B,
mean of triplicate cDNA preparations; in D, n = 24 fields per condition.
Fig. 6. Neutralization of tau seeding occurs via established TRIM21 degra-
dative pathways. (A) Effect of proteasome inhibitor MG132 on neutraliza-
tion by 5A6. (B–D) Effect of VCP inhibitors (B) DBeQ, (C) ML240, or (D) VCP
knockdown on neutralization by 5A6. (E) Immunoblot for VCP and β-actin
after VCP-directed or control (CTRL) siRNA treatment. (F and G) Effect of
(F) ATG12 depletion by siRNA or (G) inhibitors 3-methyladenine (3mA) and
chloroquine (CQ) on neutralization of tau seeding. *Unpaired t test P < 0.02;
***P < 0.0001. Error denotes SEM. In B–E, n = 12 fields per condition.
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However, the mechanisms by which antibodies exert their activity is
unclear. Mechanisms that have been described include the clear-
ance by FcγRs expressed on microglia (37), the blockade of tau
assemblies from entering neurons (20), the uptake of antibodies in
an FcγRII/III-dependent manner and subsequent colocalization
with tau in an endolysosomal compartment (24), and the uptake of
uncomplexed antibodies by neurons via unknown mechanisms and
degradation of soluble tau toxic precursors via TRIM21 (13). The
relevance of mechanisms in which interaction with an FcγR is re-
quired has recently been questioned by the finding that an anti-tau
antibody mutated to prevent FcγR binding remains protective in
mice (26). This is consistent with our in vitro findings that FcγR
interactions neither promote nor inhibit tau aggregation in neu-
ronal cell lines. Use of mutated ‘“effectorless” antibodies may be
favorable in therapeutic settings, as it would minimize the proin-
flammatory effects of extracellular tau immune complexes. Impor-
tantly, however, the mutations used to render antibody effectorless
do not affect the TRIM21 binding site, and would therefore main-
tain full levels of TRIM21 binding. Observations of antibody pro-
tection in mouse models of tau pathology are therefore consistent
with Trim21-mediated protection. In vivo experiments in a Trim21
null setting are necessary to determine the contribution of cy-
toplasmic degradation and neutralization to immunotherapeu-
tic protection against tau pathology.
Our results demonstrate that antibodies can direct a potent
TRIM21-dependent neutralizing response immediately after cyto-
solic entry of tau seeds. The selective targeting of pathological pro-
teins in the intracellular domain by antibodies may provide an
effective therapeutic strategy.
Materials and Methods
Seeding Assays. A full description of experimental techniques is provided in SI
Materials and Method. Recombinant, heparin-assembled tau preparations
were added to HEK293 or SHSY-5Y cells expressing P301S tau-venus in 96-
well plates. LF was added at 0.5 μL per well where indicated. Seeded cells
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Adenovirus Infection.Mouse primary neurons and other cells were challenged
with E1E3-deleted human adenovirus type 5 vector in the presence or absence
of anti-hexon antibody 9C12, as before.
1. Mallery DL, et al. (2010) Antibodies mediate intracellular immunity through tripartite
motif-containing 21 (TRIM21). Proc Natl Acad Sci USA 107(46):19985–19990.
2. McEwan WA, et al. (2012) Regulation of virus neutralization and the persistent
fraction by TRIM21. J Virol 86(16):8482–8491.
3. McEwan WA, et al. (2013) Intracellular antibody-bound pathogens stimulate immune
signaling via the Fc receptor TRIM21. Nat Immunol 14(4):327–336.
4. James LC, Keeble AH, Khan Z, Rhodes DA, Trowsdale J (2007) Structural basis for
PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc Natl Acad Sci USA
104(15):6200–6205.
5. Hauler F, Mallery DL, McEwan WA, Bidgood SR, James LC (2012) AAA ATPase p97/VCP
is essential for TRIM21-mediated virus neutralization. Proc Natl Acad Sci USA 109(48):
19733–19738.
6. Goedert M (2015) Neurodegeneration. Alzheimer’s and Parkinson’s diseases: The
prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 349(6248):
1255555.
7. Clavaguera F, et al. (2009) Transmission and spreading of tauopathy in transgenic
mouse brain. Nat Cell Biol 11(7):909–913.
8. Frost B, Jacks RL, Diamond MI (2009) Propagation of tau misfolding from the outside
to the inside of a cell. J Biol Chem 284(19):12845–12852.
9. Guo JL, Lee VM-Y (2011) Seeding of normal Tau by pathological Tau conformers
drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286(17):15317–15331.
10. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes.
Acta Neuropathol 82(4):239–259.
11. Watkinson RE, McEwanWA, Tam JCH, Vaysburd M, James LC (2015) TRIM21 promotes
cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized vi-
rus. PLoS Pathog 11(10):e1005253.
12. Fan W, et al. (2016) Swine TRIM21 restricts FMDV infection via an intracellular neu-
tralization mechanism. Antiviral Res 127:32–40.
13. Kondo A, et al. (2015) Antibody against early driver of neurodegeneration cis P-tau
blocks brain injury and tauopathy. Nature 523(7561):431–436.
14. Zhang Y, et al. (2014) An RNA-sequencing transcriptome and splicing database of
glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34(36):11929–11947.
15. Uhlén M, et al. (2015) Proteomics. Tissue-based map of the human proteome. Science
347(6220):1260419.
16. Hasegawa M, et al. (1996) Characterization of mAb AP422, a novel phosphorylation-
dependent monoclonal antibody against tau protein. FEBS Lett 384(1):25–30.
17. Yoshida H, Goedert M (2006) Sequential phosphorylation of tau protein by cAMP-
dependent protein kinase and SAPK4/p38delta or JNK2 in the presence of heparin
generates the AT100 epitope. J Neurochem 99(1):154–164.
18. Johnson GV, et al. (1997) The tau protein in human cerebrospinal fluid in Alzheimer’s
disease consists of proteolytically derived fragments. J Neurochem 68(1):430–433.
19. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA (1989) Multiple iso-
forms of human microtubule-associated protein tau: Sequences and localization in
neurofibrillary tangles of Alzheimer’s disease. Neuron 3(4):519–526.
20. Yanamandra K, et al. (2013) Anti-tau antibodies that block tau aggregate seeding
in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80(2):
402–414.
21. Bray N (2015) Neurodegenerative diseases: A tale of two taus in traumatic brain in-
jury. Nat Rev Drug Discov 14(9):599.
22. Falcon B, et al. (2015) Conformation determines the seeding potencies of native and
recombinant Tau aggregates. J Biol Chem 290(2):1049–1065.
23. McEwan WA, James LC (2015) TRIM21-dependent intracellular antibody neutraliza-
tion of virus infection. Prog Mol Biol Transl Sci 129:167–187.
24. Congdon EE, Gu J, Sait HBR, Sigurdsson EM (2013) Antibody uptake into neurons
occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite
for acute tau protein clearance. J Biol Chem 288(49):35452–35465.
25. Gu J, Congdon EE, Sigurdsson EM (2013) Two novel Tau antibodies targeting the 396/
404 region are primarily taken up by neurons and reduce Tau protein pathology.
J Biol Chem 288(46):33081–33095.
26. Lee S-H, et al. (2016) Antibody-mediated targeting of tau in vivo does not require
effector function and microglial engagement. Cell Reports 16(6):1690–1700.
27. Chou T-F, et al. (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-
dependent and autophagic protein clearance pathways. Proc Natl Acad Sci USA
108(12):4834–4839.
28. Chou T-F, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ (2013) Structure-activity re-
lationship study reveals ML240 and ML241 as potent and selective inhibitors of p97
ATPase. ChemMedChem 8(2):297–312.
29. Harris H, Rubinsztein DC (2011) Control of autophagy as a therapy for neurodegen-
erative disease. Nat Rev Neurol 8(2):108–117.
30. Myeku N, et al. (2016) Tau-driven 26S proteasome impairment and cognitive dys-
function can be prevented early in disease by activating cAMP-PKA signaling. Nat
Med 22(1):46–53.
31. Jackson SJ, et al. (2016) Short fibrils constitute the major species of seed-competent
tau in the brains of mice transgenic for human P301S tau. J Neurosci 36(3):762–772.
32. Barthelme D, Sauer RT (2016) Origin and functional evolution of the Cdc48/p97/VCP
AAA+ protein unfolding and remodeling machine. J Mol Biol 428(9 Pt B):1861–1869.
33. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy
targeting pathological tau conformers in a tangle mouse model reduces brain pa-
thology with associated functional improvements. J Neurosci 27(34):9115–9129.
34. Chai X, et al. (2011) Passive immunization with anti-Tau antibodies in two transgenic
models: Reduction of Tau pathology and delay of disease progression. J Biol Chem
286(39):34457–34467.
35. Sankaranarayanan S, et al. (2015) Passive immunization with phospho-tau antibodies
reduces tau pathology and functional deficits in two distinct mouse tauopathy
models. PLoS One 10(5):e0125614.
36. Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer’s disease.
Trends Mol Med 21(6):394–402.
37. Funk KE, Mirbaha H, Jiang H, Holtzman DM, Diamond MI (2015) Distinct therapeutic
mechanisms of tau antibodies: Promoting microglial clearance versus blocking neu-
ronal uptake. J Biol Chem 290(35):21652–21662.
38. Goedert M, Jakes R (1990) Expression of separate isoforms of human tau protein:
Correlation with the tau pattern in brain and effects on tubulin polymerization.
EMBO J 9(13):4225–4230.
39. Goedert M, et al. (1996) Assembly of microtubule-associated protein tau into Alz-
heimer-like filaments induced by sulphated glycosaminoglycans. Nature 383(6600):
550–553.
40. Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer
paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron
8(1):159–168.
41. Yoshimi R, Ishigatsubo Y, Ozato K (2012) Autoantigen TRIM21/Ro52 as a possible
target for treatment of systemic lupus erythematosus. Int J Rheumatol 2012:718237.
42. Beaudoin GMJ, 3rd, et al. (2012) Culturing pyramidal neurons from the early post-
natal mouse hippocampus and cortex. Nat Protoc 7(9):1741–1754.
43. Varghese R, Mikyas Y, Stewart PL, Ralston R (2004) Postentry neutralization of ade-
novirus type 5 by an antihexon antibody. J Virol 78(22):12320–12332.
44. Mercken M, et al. (1992) Monoclonal antibodies with selective specificity for Alz-
heimer Tau are directed against phosphatase-sensitive epitopes. Acta Neuropathol
84(3):265–272.
McEwan et al. PNAS | January 17, 2017 | vol. 114 | no. 3 | 579
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
